Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accounts Payables (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Accounts Payables for 7 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 163.4% to $11.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.0 million through Dec 2025, up 163.4% year-over-year, with the annual reading at $11.0 million for FY2025, 163.4% up from the prior year.
  • Accounts Payables hit $11.0 million in Q4 2025 for Eton Pharmaceuticals, down from $14.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $14.3 million in Q3 2025 to a low of $1.1 million in Q3 2022.
  • Historically, Accounts Payables has averaged $3.8 million across 5 years, with a median of $2.1 million in 2022.
  • Biggest five-year swings in Accounts Payables: crashed 67.8% in 2022 and later soared 469.25% in 2025.
  • Year by year, Accounts Payables stood at $1.8 million in 2021, then fell by 0.45% to $1.8 million in 2022, then rose by 4.64% to $1.8 million in 2023, then surged by 125.49% to $4.2 million in 2024, then surged by 163.4% to $11.0 million in 2025.
  • Business Quant data shows Accounts Payables for ETON at $11.0 million in Q4 2025, $14.3 million in Q3 2025, and $12.1 million in Q2 2025.